IndexIQ Advisors’s Neurocrine Biosciences NBIX Stock Holding History

IndexIQ Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$27K	Buy	+292	New	+$24.7K	﹤0.01%	1194

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

IndexIQ Advisors's NBIX Position: Q1 2022 in Review

IndexIQ Advisors opened a new position in Neurocrine Biosciences (NBIX) in Q1 2022: 292 shares worth $27K. The stake represents ﹤0.01% of the portfolio and ranks #1194 among its holdings.

426 funds tracked by Wall St. Rank hold NBIX as of Q1 2022.

IndexIQ Advisors held 292 shares of Neurocrine Biosciences worth $27K as of Q1 2022.
Neurocrine Biosciences was a new IndexIQ Advisors position in Q1 2022.
Neurocrine Biosciences made up ﹤0.01% of IndexIQ Advisors's portfolio in Q1 2022, its #1194 holding.
426 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2022.

Based on IndexIQ Advisors's 13F filing for Q1 2022, filed 6 May 2022.